A 12-month course of epicutaneous immunotherapy with a patch that contained 250 μg of peanut protein was associated with significant desensitization to peanut protein compared with placebo in peanut-allergic children aged 1 to 3 years, according to results from the phase 3 EPITOPE study.
CU Anschutz
Fitzsimons Building
13001 East 17th Place
Aurora, CO 80045